论文部分内容阅读
靛玉红B_2(indirubin B_1(系我所药化室合成的靛玉红衍生物之一。经薄层层析鉴定为较纯的化合物,其理化性质及结构目前正在研究之中,抗肿瘤试验证明靛玉红B_1在动物耐受剂量下(1g/Kg/day×5—9),可以明显延长淋巴细胞型白血病L_(7212)和L_(7712)小鼠的生存时间,延存率分别为45～54％和26～28％(P均<0.001)。亦可明显抑制实体肿瘤大鼠W_(256)和小鼠Lewis肺癌的生长,抑制率分别为52～62％和37％(P均<0.01)。对小鼠淋巴细胞型白血病L_(615)没有明显的治疗作用。并经病理切片初步观察到:靛玉红B_1治疗的L_(7212)小鼠肝、脾细胞核分裂指数下降、白血病细胞浸润度降低。
Indirubin B_1 (indirubin B_1) is one of the derivatives of indirubin synthesized by our pharmacy department. It is identified as a relatively pure compound by thin layer chromatography. Its physicochemical properties and structure are currently under investigation. It was proved that the indirubin B1 can significantly prolong the survival time of L_(7212) and L_(7712) mice of lymphoblastic leukemia at the dose tolerance of animals (1g/Kg/day×5-9). 45～54% and 26～28% (P<0.001).The growth of W_(256) and Lewis lung cancer in rats with solid tumors were also significantly inhibited. The inhibition rates were 52~62% and 37%, respectively. <0.01).There was no obvious therapeutic effect on mouse lymphocytic leukemia L_(615), and it was initially observed by pathological section that: Insulin red B_1 treated L_(7212) mice had decreased mitotic index of liver and spleen cells and leukemia. Cell infiltration is reduced.